Small Cell Lung Cancers (SCLCs) With Short Survival Subgroup


There were no clinically significant predictors of therapy response, and therapeutic alternatives were restricted. For 108 SCLCs, clinical data and somatic mutations of MSK-IMPACT panel genes were collected from cBioPortal and examined to discover mutated gene networks. The outcomes were confirmed in a separate cohort of 54 SCLCs, whose data was obtained via cBioPortal. Short and long survivors’ tumors showed different networks. The degree (K) and betweenness (B) of a gene in its linked mutation network are important characteristics. About 2 fingerprints of mutant genes were found by comparing their B/K ratios, identifying short (IL-7R, NTRK2, HNF-1A) and long survivors (NBN, PTPN-11, IRS-1, INPP-4A, PIK-3CG, HGF, LATS-2, SMARCA-4, FLT-3, EIF-4A2, SPEN, PAX-5, SH2-D1A, ARID-1A, HOXB-13, ERCC-4, FANCA, FH, FGFR-2, MST-1R, SMAD-4, DDR-2, IGF-1R, PIK-3CB). Patients with at least one mutant gene in the brief signature had a lower median overall survival of 8 months than 28 months (P<0.001). Patients with at least one altered gene in the long signature had a greater overall survival rate of 39 months than 20 months (P=0.004). The brief signature’s worth was also confirmed in a separate group of SCLCs. The mutant genes network may be used to subclassify SCLCs based on somatic mutations and identify a subpopulation of tumors with a bad prognosis.

Source:www.clinical-lung-cancer.com/article/S1525-7304(22)00108-5/fulltext



Source link

Leave a Reply

Your email address will not be published.

Back To Top